Frotscher Birgit, Anton Katrin, Worm Margitta
Department of Dermatology and Allergy, Charité, Campus Virchow Klinikum, Humboldt Universität zu Berlin, Germany.
J Invest Dermatol. 2002 Nov;119(5):1059-64. doi: 10.1046/j.1523-1747.2002.19531.x.
The aim of this study was to examine whether the immune modulator resiquimod, which belongs like imiquimod to the imidazoquinolines, is capable of influencing IgE synthesis. Peripheral blood mono-nuclear cells from normal donors and patients with atopic dermatitis and with seasonal allergic rhinitis were analyzed in the presence of resiquimod, anti-CD40+interleukin-4 stimulation for induction of IgE, and anti-CD40+interleukin-4 in the presence of resiquimod, respectively. Our data show that spontaneous IgE production was inhibited in the presence of resiquimod, which was strongest at 10 ng per ml in both groups of allergic patients. Inhibition of IgE production after anti-CD40+interleukin-4 stimulation in the presence of resiquimod (10 ng per ml) was comparable between all the groups. In normal donors median inhibition of IgE synthesis was 93%, in seasonal allergic rhinitis patients 77%, and in patients with atopic dermatitis 72%. In order to rule out antiproliferative effects of resiquimod, which might influence IgE production, we also studied proliferation of peripheral blood mononuclear cells from normal donors, which remained unchanged in the presence of resiquimod at 0.1-10 ng per ml but was inhibited at 100 or 1000 ng per ml. In search of possible mechanisms responsible for the observed inhibition of IgE production, we analyzed the expression and production of molecules that are known to modulate IgE production, namely CD23 and interferon-gamma. CD23 expression on B cells was lower in the presence of resiquimod (10 ng per ml) in anti-CD40+interleukin-4 stimulated cells, whereas interferon-gamma was strongly induced (4-6-fold) by resiquimod (10 ng per ml). Furthermore, by using neutralizing interferon-gamma monoclonal antibodies, we show that inhibition of IgE production occurred in an interferon-gamma-dependent manner. Taken together our results show that resiquimod is a potent modulator of IgE production in vitro in normal but also in allergic donors.
本研究的目的是检验免疫调节剂瑞喹莫德(它与咪喹莫德一样属于咪唑喹啉类)是否能够影响IgE的合成。分别在有瑞喹莫德存在的情况下、抗CD40加白细胞介素-4刺激以诱导IgE时以及抗CD40加白细胞介素-4且有瑞喹莫德存在的情况下,对来自正常供者、特应性皮炎患者和季节性变应性鼻炎患者的外周血单个核细胞进行了分析。我们的数据表明,在有瑞喹莫德存在的情况下,自发性IgE产生受到抑制,这在两组变应性患者中均在每毫升10纳克时最为明显。在有瑞喹莫德(每毫升10纳克)存在的情况下,抗CD40加白细胞介素-4刺激后IgE产生的抑制在所有组中相当。在正常供者中,IgE合成的中位抑制率为93%,在季节性变应性鼻炎患者中为77%,在特应性皮炎患者中为72%。为了排除瑞喹莫德可能影响IgE产生的抗增殖作用,我们还研究了正常供者外周血单个核细胞的增殖情况,其在每毫升0.1 - 10纳克的瑞喹莫德存在时保持不变,但在每毫升100或1000纳克时受到抑制。为了探寻导致所观察到的IgE产生抑制的可能机制,我们分析了已知可调节IgE产生的分子即CD23和干扰素-γ的表达及产生情况。在抗CD40加白细胞介素-4刺激的细胞中,有瑞喹莫德(每毫升10纳克)存在时B细胞上的CD23表达较低,而瑞喹莫德(每毫升10纳克)强烈诱导干扰素-γ(4 - 6倍)产生。此外,通过使用中和干扰素-γ单克隆抗体,我们表明IgE产生的抑制是以干扰素-γ依赖的方式发生的。综上所述,我们的结果表明,瑞喹莫德在体外对正常供者以及变应性供者而言都是IgE产生的有效调节剂。